Piper Jaffray & Co. initiates coverage on Genzyme (Nasdaq: GENZ) with a Buy rating and $86 price target, citing steady growth with highly achievable catalysts.

Piper analyst says, “We believe GENZ shares offer steady growth with highly achievable NT catalysts. NT visibility into earnings combined with sophisticated use of its balance sheet for clinical partnerships puts the company in a stronger position to offer reliable growth at a highly reasonable price (currently trading at 11x our 2009 EPS forecast). Moreover, following the closing of Roche’s acquisition of DNA, we expect GENZ to be well positioned to capture a redeployment of profits…

Smart Investors Are Quietly Loading Up on These “Dividend Legends”

If you want your portfolio to pay you cash like clockwork, it’s time to stop blindly following conventional wisdom like relying on Dividend Aristocrats.

There’s a better option, and we want to show you. We’re offering a brand-new report on 2 stocks we believe offer the rare combination of a high dividend yield and significant stock appreciation upside.

If you’re tired of feeling one step behind in this market, this free report is a must-read for you.

Thanks! We will redirect you shortly to the free report!

By providing your email address, you agree to receive communications from us regarding website updates and other offerings that may be of interest to you.
You have the option to opt-out of these emails at any moment. For more information, please review our Disclaimer and Terms of Use.